Wednesday, 04 May 2016
A shocking new science study funded by the Alberta Ministry of Health and published in the VACCINE science journal has found that nearly 10 percent of Canadian females end up in emergency rooms (the “Emergency Department” in Canadian vernacular) following HPV vaccine injections.
The study is entitled Adverse events following HPV vaccination, Alberta 2006-2014 and is also found at this source .
Even more shockingly, vaccine researchers funded by the Alberta Ministry of Health declare this 10% emergency room visitation rate to be “low” and “consistent with those seen elsewhere [with vaccines].” If 100 people drink contaminated water and 10 end up in ER from it, would this be pretty normal, “low” or would we see lawsuits left and right?
This shocking admission unveils a highly disturbing truth about routine vaccinations given to children and teens: They are well known to cause emergency room visits, hospitalizations and adverse effects among those receiving them. This science paper, in fact, just confirmed all that while calling the entire phenomenon safe.
195,270 girls tracked after receiving HPV vaccine injections… 9.9% ended up in emergency rooms in just 42 days
In the study, authored by Xianfang C. Liu and others, 195,270 females received one or more HPV vaccine injections and were monitored for 42 days.
As the study clearly states in its results, ” Of the women who received HPV vaccine 958 were hospitalized and 19,351 had an [Emergency Department] visit within 42 days of immunization.”
That’s 9.9% of the females receiving the injections. Not only were 19,351 sent to emergency rooms, 958 of the females were hospitalized, meaning they endured overnight stays at the hospital to treat some serious condition. That comes to about 1 out of every 200 persons receiving the vaccine injection.
None of this is surprising to those who are aware of 75% of vaccine recipients in a Mexican town winding up hospitalized or dead following vaccinations .
Here’s a capture from the study itself, admitting the 19,351 who ended up in the Emergency Department (ED).
Vaccine. 2016 Apr 4;34(15):1800-5. doi: 10.1016/j.vaccine.2016.02.040. Epub 2016 Feb 26.
Adverse events following HPV vaccination, Alberta 2006-2014.
In Canada, private purchase of human papilloma virus (HPV) vaccines has been possible since 2006. In Alberta, Canada, a publicly funded quadrivalent HPV vaccine program began in the 2008/2009 school year. There have been concerns about adverse events, including venous thromboembolism (VTE) associated with HPV vaccines. We describe the frequencies of adverse events following HPV vaccination among Alberta females aged 9 years or older and look at VTE following HPV vaccination.
We used the Alberta Immunization and Adverse Reaction to Immunization (Imm/ARI) repository (publicly funded vaccine), the population-based Pharmaceutical Information Network (PIN) information system (dispensing of a vaccine), and the Alberta Morbidity and Ambulatory Care Abstract reporting system (MACAR) for June 1, 2006-November 19, 2014. Deterministic data linkage used unique personal identifiers. We identified all reported adverse events following immunization (AEFI) and all emergency department (ED) utilization or hospitalizations within 42 days of immunization. We calculated the frequency of AEFI by type, rates per 100,000 doses of HPV vaccine administered and the frequencies of ICD-10-CA codes for hospitalizations and emergency department visits.
Over the period 195,270 females received 528,913 doses of HPV vaccine. Of those receiving at least one dose, 192 reported one or more AEFI events (198 AEFI events), i.e., 37.4/100,000 doses administered (95% CI 32.5-43.0). None were consistent with VTE. Of the women who received HPV vaccine 958 were hospitalized and 19,351 had an ED visit within 42 days of immunization. Four women who had an ED visit and hospitalization event were diagnosed with VTE. Three of these had other diagnoses known to be associated with VTE; the fourth woman had VTE among ED diagnoses but not among those for the hospitalization.
Rates of AEFI after HPV immunization in Alberta are low and consistent with types of events seen elsewhere.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.
*Papillomavirus vaccines/ae [adverse effects]; *Product surveillance; *Vaccination/ae [adverse effects]; Alberta; Canada; HPV vaccination; Humans; Population surveillance; Postmarketing